DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
Newron Pharmaceut.
WKN: A0LF18 / Name: Newron Pharmaceut. / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
11,20 €
-0,71 %
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
| Unlocking Potential: Discover the transformative power of MetroEHS Pediatric Therapy. Our dedicated team of therapists specializes in ABA, speech, occupational, and feeding therapy, ensuring personalized care for your child's success. Embrace a brighter future with our comprehensive mental health services and convenient teletherapy options.
Neueste Beiträge
lewishamilton in Yili Group's Chinese Style Bus Makes Grand Entrance in Paris, Showcasing Unwavering Support for Chinese Athletes and the Olympic Spirit, Inner Mongolia Yili Industrial Group Co Ltd